Clinically proven GLP-1 medications prescribed by licensed physicians. Average weight loss of 15-20% body weight in clinical trials.
Prescription-strength GLP-1 medications backed by clinical research.
Weekly injection that reduces appetite and slows gastric emptying for sustainable weight loss.
Dual-action GIP/GLP-1 agonist delivering superior weight loss results in clinical trials.
Daily tablet form of semaglutide for those who prefer not to inject.
GLP-1 medication plus nutritional support, coaching, and metabolic supplements.
Start your weight loss journey in three easy steps.
Complete a comprehensive health questionnaire about your weight history, medical conditions, and goals.
A licensed physician reviews your information and determines if GLP-1 therapy is right for you.
Your medication is shipped in a temperature-controlled package directly to your door.
A realistic timeline of your weight loss progress with GLP-1 therapy.
Start with a low dose to minimize side effects. You may notice reduced appetite within the first week. Some experience mild nausea as your body adjusts.
Dose increases to therapeutic levels. Appetite significantly reduced. Many patients report feeling satisfied with smaller portions and fewer cravings.
Maximum dose achieved. This is when you'll see the most dramatic changes. Clothes fit better, energy increases, and health markers improve.
Continued treatment maintains weight loss. Many patients see 15-20% total body weight reduction. Work with your doctor on long-term maintenance strategy.
Hear from patients who've achieved their weight loss goals.
Everything you need to know about GLP-1 weight loss medications.
GLP-1 (glucagon-like peptide-1) medications mimic a natural hormone that regulates appetite and blood sugar. They work by slowing stomach emptying, reducing hunger signals to the brain, and helping you feel satisfied with less food. This leads to significant, sustainable weight loss.
Semaglutide (Wegovy/Ozempic) is a GLP-1 agonist, while Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist. Clinical trials show Tirzepatide produces slightly greater weight loss (up to 22% vs 15%), but both are highly effective. Your doctor will help determine which is best for your situation.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These typically occur during dose increases and improve over time. Starting with a low dose and titrating slowly helps minimize side effects. Serious side effects are rare but will be discussed with your physician.
GLP-1 medications are typically prescribed for adults with a BMI of 30+ (obese) or 27+ with at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. They're not recommended for people with personal or family history of medullary thyroid cancer or MEN2 syndrome.
Clinical trials show average weight loss of 15% with Semaglutide and up to 22% with Tirzepatide over 68-72 weeks. Individual results vary based on starting weight, adherence, diet, and exercise. Many patients see 5-10% weight loss within the first 3 months.
Studies show that many patients regain weight after stopping GLP-1 medications, similar to other chronic conditions requiring ongoing treatment. This is why we focus on building sustainable habits during treatment and work with you on a long-term maintenance plan.
Insurance coverage varies widely. Many plans now cover GLP-1s for diabetes but fewer cover them for weight loss alone. We offer competitive self-pay pricing using compounded medications that are often more affordable than brand-name versions through insurance.
Injectable forms (Semaglutide and Tirzepatide) are given as a once-weekly subcutaneous injection using a small, easy-to-use pen. You can inject in your abdomen, thigh, or upper arm. Oral Semaglutide is taken as a daily tablet on an empty stomach with a small amount of water.